- Home
- SGA vs IKNA Comparison
SGA vs IKNA Comparison
Compare SGA & IKNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGA
- IKNA
- Stock Information
- Founded
- SGA 1986
- IKNA 2016
- Country
- SGA United States
- IKNA United States
- Employees
- SGA N/A
- IKNA N/A
- Industry
- SGA Broadcasting
- IKNA Biotechnology: Pharmaceutical Preparations
- Sector
- SGA Consumer Discretionary
- IKNA Health Care
- Exchange
- SGA Nasdaq
- IKNA Nasdaq
- Market Cap
- SGA 89.2M
- IKNA 80.8M
- IPO Year
- SGA 1992
- IKNA 2021
- Fundamental
- Price
- SGA $12.62
- IKNA $1.73
- Analyst Decision
- SGA
- IKNA Buy
- Analyst Count
- SGA 0
- IKNA 2
- Target Price
- SGA N/A
- IKNA $3.00
- AVG Volume (30 Days)
- SGA 16.0K
- IKNA 58.7K
- Earning Date
- SGA 11-07-2024
- IKNA 11-07-2024
- Dividend Yield
- SGA 8.02%
- IKNA N/A
- EPS Growth
- SGA N/A
- IKNA N/A
- EPS
- SGA 0.75
- IKNA N/A
- Revenue
- SGA $110,669,000.00
- IKNA $659,000.00
- Revenue This Year
- SGA $0.49
- IKNA N/A
- Revenue Next Year
- SGA $0.18
- IKNA N/A
- P/E Ratio
- SGA $16.82
- IKNA N/A
- Revenue Growth
- SGA N/A
- IKNA N/A
- 52 Week Low
- SGA $11.71
- IKNA $1.22
- 52 Week High
- SGA $27.00
- IKNA $2.32
- Technical
- Relative Strength Index (RSI)
- SGA 39.51
- IKNA 54.06
- Support Level
- SGA $11.71
- IKNA $1.71
- Resistance Level
- SGA $14.09
- IKNA $1.72
- Average True Range (ATR)
- SGA 0.41
- IKNA 0.05
- MACD
- SGA -0.08
- IKNA -0.00
- Stochastic Oscillator
- SGA 38.24
- IKNA 53.85
About SGA Saga Communications Inc. (FL)
Saga Communications Inc is a broadcast company engaged in acquiring, developing, and operating broadcast properties. The company's objective is to operate top billing radio stations in mid-sized markets and It derives a majority of its revenue from the sale of advertising for broadcast on its stations.
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.